Post consolidation therapy for adult patients with acute myeloid leukaemia.

2.50
Hdl Handle:
http://hdl.handle.net/10541/108427
Title:
Post consolidation therapy for adult patients with acute myeloid leukaemia.
Authors:
Ranson, Malcolm R; Scarffe, J Howard; Morgenstern, Godfrey R; Chang, James; Anderson, Heather; Deakin, David P; Oppenheim, B; Heron, D; Ryder, W David J
Abstract:
One hundred and sixteen adult patients aged 14-73 with previously untreated acute myeloid leukaemia received induction and consolidation chemotherapy with daunorubicin, cytosine arabinoside and thioguanine. Two novel approaches to post consolidation therapy have been investigated. Patients aged 50 years or less who had no suitable matched allogeneic donor were considered for autologous bone marrow transplantation (BMT) using bone marrow which had been cultured in vitro for 14 d. Patients over the age of 50 years with normal bone marrow cellularity and peripheral blood count were treated with a single oral dose of busulphan 100 mg/m2 (without BMT rescue) 3 months following the completion of consolidation therapy. Eighty-seven patients (75%) achieved a complete remission. Of 70 patients who completed consolidation therapy, 40 were aged less than or equal to 50 years and 30 were greater than 50 years. Forty-three patients went on to receive post consolidation therapy in first CR (autologous BMT 12, allogeneic BMT 7, busulphan therapy 24). The event-free survival at 4 years was 47% for autologous BMT, 34% for allogeneic BMT and 45% for busulphan-treated patients. The survival for the older cohort of patients who received post consolidation therapy with single dose busulphan therapy was encouraging, and this agent should be considered for future post consolidation strategies.
Affiliation:
Department of Medical Oncology, CRC University of Manchester.
Citation:
Post consolidation therapy for adult patients with acute myeloid leukaemia. 1991, 79 (2):162-9 Br. J. Haematol.
Journal:
British Journal of Haematology
Issue Date:
Oct-1991
URI:
http://hdl.handle.net/10541/108427
DOI:
10.1111/j.1365-2141.1991.tb04517.x
PubMed ID:
1958473
Type:
Article
Language:
en
ISSN:
0007-1048
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorRanson, Malcolm Ren
dc.contributor.authorScarffe, J Howarden
dc.contributor.authorMorgenstern, Godfrey Ren
dc.contributor.authorChang, Jamesen
dc.contributor.authorAnderson, Heatheren
dc.contributor.authorDeakin, David Pen
dc.contributor.authorOppenheim, Ben
dc.contributor.authorHeron, Den
dc.contributor.authorRyder, W David Jen
dc.date.accessioned2010-07-27T13:03:47Z-
dc.date.available2010-07-27T13:03:47Z-
dc.date.issued1991-10-
dc.identifier.citationPost consolidation therapy for adult patients with acute myeloid leukaemia. 1991, 79 (2):162-9 Br. J. Haematol.en
dc.identifier.issn0007-1048-
dc.identifier.pmid1958473-
dc.identifier.doi10.1111/j.1365-2141.1991.tb04517.x-
dc.identifier.urihttp://hdl.handle.net/10541/108427-
dc.description.abstractOne hundred and sixteen adult patients aged 14-73 with previously untreated acute myeloid leukaemia received induction and consolidation chemotherapy with daunorubicin, cytosine arabinoside and thioguanine. Two novel approaches to post consolidation therapy have been investigated. Patients aged 50 years or less who had no suitable matched allogeneic donor were considered for autologous bone marrow transplantation (BMT) using bone marrow which had been cultured in vitro for 14 d. Patients over the age of 50 years with normal bone marrow cellularity and peripheral blood count were treated with a single oral dose of busulphan 100 mg/m2 (without BMT rescue) 3 months following the completion of consolidation therapy. Eighty-seven patients (75%) achieved a complete remission. Of 70 patients who completed consolidation therapy, 40 were aged less than or equal to 50 years and 30 were greater than 50 years. Forty-three patients went on to receive post consolidation therapy in first CR (autologous BMT 12, allogeneic BMT 7, busulphan therapy 24). The event-free survival at 4 years was 47% for autologous BMT, 34% for allogeneic BMT and 45% for busulphan-treated patients. The survival for the older cohort of patients who received post consolidation therapy with single dose busulphan therapy was encouraging, and this agent should be considered for future post consolidation strategies.en
dc.language.isoenen
dc.subjectMyeloid Leukaemiaen
dc.subject.meshAcute Disease-
dc.subject.meshAdolescent-
dc.subject.meshAdult-
dc.subject.meshAged-
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols-
dc.subject.meshBone Marrow Transplantation-
dc.subject.meshBusulfan-
dc.subject.meshCombined Modality Therapy-
dc.subject.meshCytarabine-
dc.subject.meshDaunorubicin-
dc.subject.meshFemale-
dc.subject.meshHumans-
dc.subject.meshLeukemia, Myeloid-
dc.subject.meshMale-
dc.subject.meshMiddle Aged-
dc.subject.meshRemission Induction-
dc.subject.meshThioguanine-
dc.subject.meshTime Factors-
dc.titlePost consolidation therapy for adult patients with acute myeloid leukaemia.en
dc.typeArticleen
dc.contributor.departmentDepartment of Medical Oncology, CRC University of Manchester.en
dc.identifier.journalBritish Journal of Haematologyen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.